13
Views
3
CrossRef citations to date
0
Altmetric
Research Article

Tumor Necrosis Factor and Interferon-γ Augment Anticolon Antibody-Dependent Cellular Cytotoxiy in Ulcerative Colitis

, , , , , , , , & show all
Pages 15-26 | Published online: 27 Sep 2008
 

Abstract

The effect of tumor necrosis factor (TNF) and interferon (IFN)-γ on antibody-dependent cellular cytotoxicity (ADCC) in patients with ulcerative colitis (UC) was investigated. ADCC activity was measured by the 51Cr release assay, using peripheral blood mononuclear cells of healthy subjects as effector cells and RPMI 4788 cells derived from human colon cancer as target cells.

ADCC activity under sera from healty subjects remained low whether or not the effector cells were pretreated with TNF (100 U/ml, 16h). Under sera from UC patients, ADCC activity of 13.9%, compared to 9.6% when pretreatment was deleted. The effect of IFN pretreatment (100U/ml, 16h) was also examined under sera from UC patients; in that experiment activity rose to 26.8%, in comparison to a 10.7% when IFN-γ pretreatment was deleted. Finally, when the effector cells were pretreated with both TNF and IFN-γ (100U/ml of each, 16h) the ADCC activity under sera from UC patients was higher than when either TNF or IFN-γ were used alone. These results suggest that TNF and IFN-γ, by increasing ADCC activity in UC lesions, are involved in cell injury in the colonic epithelium, IFN-γ appears to increase ADCC activity by increasing the number of high affinity monocyte FcγRI receptors, while TNF increases ADCC activity by a different mechanism.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.